Revocation of the drug Avastin November 18, 2011 Today, FDA Commissioner Dr. Margaret Hamburg announced the revocation of the drug Avastin for treatment of metastatic breast cancer, agreeing with the recent unanimous recommendation of the Oncologic Drug Advisory Committee (ODAC). Breast Cancer Action supports Dr. Hamburg’s decision to revoke Avastin for metastatic breast cancer based on existing science. Since 2007, BCAction has actively opposed the use of Avastin for metastatic breast cancer patients because of its failure to improve overall survival or quality of life and its serious side effects. As a former BCAction board member testified before the FDA panel: “We all want better treatments for women with metastatic.